FRS3 and prostate carcinoma: For example, Wang et al. found that the splicing pattern of fibroblast growth factor receptor substrate 3, tuberous sclerosis 2, and RAS guanyl releasing protein 2 has significant race-related differences among prostate cancer patients (Wang et al., 2017).